Drugs / VSN16R
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02542787 | Aug 2015 → Oct 2017 | multiple sclerosis | Canbex Therapeutics Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VSN16R | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02542787 ↗ |
| Known as | VP1218-59-42 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068565 ↗ |
| Modality | Small molecule | “Small molecule” NCT02542787 ↗ |
| Route | Oral | “oral capsules” NCT02542787 ↗ |